EHI
MLTX icon

Eagle Health Investments’s MoonLake Immunotherapeutics MLTX Stock Holding History

Eagle Health Investments’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-187,600
Closed -$2.47M – 32
2025
Q4 		$2.47M Buy
+187,600
New +$2.21M 0.54% 26

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Eagle Health Investments's MLTX Position: Q1 2026 in Review

Eagle Health Investments sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 187,600 shares — an estimated $2.47M sold.

Eagle Health Investments first reported a position in MLTX in Q4 2025 and held it in 1 quarter. The position peaked at $2.47M in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Eagle Health Investments reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Eagle Health Investments sold 187,600 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $2.47M.
  • Eagle Health Investments first reported a position in MoonLake Immunotherapeutics in Q4 2025 and held it in 1 quarter.
  • Eagle Health Investments's MoonLake Immunotherapeutics position peaked at $2.47M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Eagle Health Investments's 13F filing for Q1 2026, filed 15 May 2026.